Patents Examined by San-ming Hui
  • Method for increasing muscle strength
    Patent number: 9510988
    Abstract: A method of increasing strength using a nutrient holding device (pedal device, hat band, necklace, locket, belt, etc.) which contains at least one nutrient which has the ability to stimulate reflex zones on the skin resulting in improved performance when worn during athletic endeavors (exercise).
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 6, 2016
    Inventor: Edward Ludwig Blendermann
  • High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
    Patent number: 9504665
    Abstract: The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: November 29, 2016
    Inventor: W. Louis Cleveland
  • Pharmaceutical compositions comprising POH derivatives
    Patent number: 9499461
    Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: November 22, 2016
    Assignee: NeOnc Technologies, Inc.
    Inventors: Thomas Chen, Daniel Levin, Satish Puppali
  • Kinase inhibitors
    Patent number: 9499535
    Abstract: The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: November 22, 2016
    Assignee: ORIGENIS GMBH
    Inventors: Michael Thormann, Andreas Treml, Michael Almstetter, Roland Koestler, Nasser Yehia
  • 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use
    Patent number: 9499502
    Abstract: The present invention discloses certain iminothiazine compounds and mono- and dioxides thereof, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein each of variables shown in the formula are as defined herein. The compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and uses, including Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: November 22, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford, Jared N. Cumming, Chad E. Bennett, Eric J. Gilbert, Jack D. Scott, Younong Yu, Xuanjia Peng
  • Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of
    Patent number: 9493436
    Abstract: A variety of benzofurans and indole derivatives some with an alkynyl linker are disclosed herein. These compounds are not highly charged at physiological pH and have good bioavailability characteristics. These compounds exhibit selective or at least preferential affinity for the active sites of various sub-sets of protein tyrosine phosphatases. Some of these compounds are excellent inhibitors of Mycobacterium protein tyrosine phosphatase B (mPTPB) a protein tyrosine phosphatase expressed in Mycobacterium tuberculosis and characterized as a virulence factor in the causal agent of tuberculosis. Accordingly, many of these compounds and pharmaceutically acceptable salts thereof are useful for the treatment of diseases such as tuberculosis.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: November 15, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Zhong-Yin Zhang, Yantao He, Li-Fan Zeng
  • Compounds, compositions, pharmaceutical compositions, and methods of use
    Patent number: 9492428
    Abstract: Certain embodiments of the invention include compositions comprising a compound of Formula (I), and salts, isomers, and derivatives thereof. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I), and salts, isomers, and derivatives thereof. Other embodiments of this invention include methods for treating disease (e.g., cancer) and methods for administering a compound of Formula (I), and salts, isomers, and derivatives thereof.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 15, 2016
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Gerald B. Hammond, Zhuang Jin, Paula J. Bates, Elsa Merit Reyes-Reyes, Abraham Vaisberg
  • Inhibitors of PFKFB3 for cancer therapy
    Patent number: 9492418
    Abstract: Compounds used to inhibit glycolytic pathway small molecule kinase 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase (PFKFB) are set forth; these inhibitors can be used in the treatment of certain diseases in which cells or tumors rely on glycolytic metabolism, such as many cancer cells.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Yong-Hwan Lee, Jeong Do Kim
  • Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases
    Patent number: 9492542
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethylindazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: November 15, 2016
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Angelo Guglielmotti, Beatrice Garrone, Alessandro Ble', Giuseppe Biondi, Roberta Petrosemolo, Enrica Biondi, Iacopo Biondi
  • Method of controlling neonicotinoid resistant hemiptera
    Patent number: 9485989
    Abstract: The invention relates to a method of controlling insects from the order hemiptera that resistant to neo-nicotinoid insecticides using spiroheterocyclic pyrrolidine dione derivatives.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: November 8, 2016
    Assignee: Syngenta Participations AG
    Inventors: Russell Slater, Alfred Rindlisbacher, Peter Maienfisch, Phillippe Camblin, Alain Gaume
  • Mineralocorticoid receptor antagonists
    Patent number: 9487506
    Abstract: Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the Formula (I) are disclosed.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: November 8, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ping Lan, Kun Liu, Anthony Ogawa, Hong Shen, Christine Yang, Yuguang Wang, Richard Beresis, Changhe Qi
  • Inhibitors of matrix metalloproteinases
    Patent number: 9487462
    Abstract: Compounds of general formula (I), salts or solvates thereof and pharmaceutical compositions containing same: wherein Z is N or CH or the Z(R1) part is replaced with a covalent bond, m and n is 0, 1, 2 or 3; HET is heteroaryl; X is CF3, halogen, CO-heterocyclyl, COOR3 or CONHR3; R1 is H, (CH2)o-aryl, (CH2)p-heteroaryl, (CH2)q-biphenyl; C(O)—R5; S(O)2—R6; R2 is H, aryl, heteroaryl, Y—(CH2)r-aryl, Y—(CH2)s-heteroaryl, where some of the above substituents may be substituted; Y is O or S; with the exclusion of the compound where HET is 1,3-thiazol, X is COOH, R1 is 4-fluorophenyl and R2 is benzyloxy. The invention also relates to the use of a compound of general formula (I), salts or solvates thereof for the use in the prevention or treatment of diseases where the activation of MMPs is involved in the pathomechanism. In this aspect the use of the above excluded compound is also inventive.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: November 8, 2016
    Assignees: PharmaHungary 2000 Kft., TargetEx Kft.
    Inventors: Péter Ferdinandy, Tamás Bálint Csont, Csaba Csonka, Krisztina Kedvesné Kupai, László Kovács, Attila Kis-Tamás, Ferenc Tamás Takács, Dénes Kónya, Gábor Medgyes, Sándor Cseh, István Hajdú, Zsolt Lörincz, György Dormán, Anikó Görbe
  • SSH-2 (slingshot-2) inhibitors and methods for making and using them
    Patent number: 9487522
    Abstract: In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment compositions of the invention slow or inhibit F-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit, or reverse, or ameliorate the progression of a cancer or a metastasis or other uncontrolled or unregulated cell growth, and/or Alzheimer's disease.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: November 8, 2016
    Assignee: The Regents of the University of California
    Inventors: Jason H. Haga, Shu Chien, Matt Mui, Marshall J. Levesque, Phillip D. Pham
  • Biocidal compositions and methods of use
    Patent number: 9474278
    Abstract: Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and an isothiazolinone compound selected from 1,2-benzisothiazolin-3-one, 2-methyl-1,2-benzisothiazolin-3-one, and mixtures thereof. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: October 25, 2016
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Bei Yin, Michael V. Enzien, Donald J. Love, Emerentiana Sianawati
  • Cyanoenamines and their use as fungicides
    Patent number: 9474275
    Abstract: The present invention relates to cyanoenamine derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: October 25, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jürgen Benting, Ulrike Wachendorff-Neumann, Philippe Desbordes, Christophe Dubost, Pierre Genix, Shinichi Narabu, Jean-Pierre Vors
  • Controlled release formulations of levodopa and uses thereof
    Patent number: 9463246
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: October 11, 2016
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Colchicine derivatives, methods and uses thereof
    Patent number: 9458101
    Abstract: The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 4, 2016
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Jack Tuszynski, Jonathan Y. Mane, John Torin Huzil, Boguslaw Tomanek, Dorota Bartusik
  • Pregnancy hormone combination for treatment of autoimmune diseases
    Patent number: 9452175
    Abstract: The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: September 27, 2016
    Assignee: The Regents of the University of California
    Inventor: Rhonda Voskuhl
  • Fluorinated arylalkylaminocarboxamide derivatives
    Patent number: 9447029
    Abstract: Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: September 20, 2016
    Assignee: NEWRON PHARMACEUTICALS S.P.A.
    Inventor: Paolo Pevarello
  • Hormone replacement formulation
    Patent number: 9446049
    Abstract: The basic formulation comprises a combination of three estrogens, 2-hydroxyestrone, 17-beta-estradiol and estriol, and a metabolite of an estrogen, 2-methoxyestradiol, in specified amounts. Amounts of folic acid, DHEA, testosterone, Vitamin B6, Di-Indolyl Methane, melatonin and progesterone, as well as selenium and cobalt can be added in specific amounts to the basic formulation. 2-Hydroxyestradiol, another metabolic, can also be added.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: September 20, 2016
    Inventor: Jonathan V. Wright